A single dose of BIVV001 is safe and effectively increases factor VIII (FVIII) activity over one month in men with…
Articles by Marisa Wexler, MS
Refixia or Rebinyn (nonacog beta pegol, or N9-GP), an approved replacement therapy for hemophilia B, is…
CB 2679d-GT, an investigational gene therapy for hemophilia B being developed by Catalyst Biosciences, can increase factor…
Approximately 30,000 males have hemophilia in the U.S., according to estimates from a recent study, which also found that…
Three hemophilia B patients said they were able to lead a relatively normal life, including being more active and…
Data from a completed Phase 2b trial indicate that dalcinonacog alfa (DalcA) is an effective and safe therapy to prevent bleeding…
The U.S. Food and Drug Administration (FDA) has accepted — under priority review — a marketing application for…
When administered at a high dose, a gene therapy for hemophilia B known as FLT180a seems able to restore the…
Esperoct (turoctocog alfa pegol) is now available in the U.S. to treat and control bleeding in adults and children…
A modified version of the coagulation protein factor X was able to significantly reduce bleeding in a mouse model of…